Press Release from NCI: NCI clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma National Cancer Institute sent this bulletin at 12/28/2022 11:09 AM EST The latest press release from the National Cancer Institute Having trouble viewing this email? View it as a Web page. You are subscribed to Press Releases from the National Cancer Institute. New press releases are listed below. NCI clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma 12/28/2022 A clinical trial led by NCI has resulted in FDA approval of the immunotherapy drug atezolizumab (Tecentriq) to treat advanced alveolar soft part sarcoma.
